Wockhardt Ltd.

Financial

	Wockhardt	Astrazeneca Pharma I	Gland Pharma
Operational Metrics
Pharmaceutical Sector
Domestic Sales Growth - YoY	10.6 %	18.6 %	n/a
R&D as a % of Total Sales	4.2 %	0.0	4.3 %
Financials
5 yr Average ROE	-3.81 %	18.37 %	14.74 %
5yr average Equity Multiplier	2.26	1.94	1.13
5yr Average Asset Turnover Ratio	0.39	0.94	0.53
5yr Avg Net Profit Margin	-4.46 %	10.03 %	24.17 %
Price to Book	7.02	32.98	2.75
P/E	0.0	231.05	34.28
5yr Avg Cash Conversion Cycle	-118.47 Days	-36.14 Days	72.51 Days
Inventory Days	68.12 Days	64.11 Days	117.52 Days
Days Receivable	71.63 Days	36.53 Days	78.29 Days
Days Payable	260.3 Days	208.62 Days	103.04 Days
5yr Average Interest Coverage Ratio	-0.67	140.96	205.64
5yr Avg ROCE	-1.45 %	23.99 %	19.61 %
5yr Avg Operating Profit Margin	3.11 %	14.51 %	32.0 %
5 yr average Debt to Equity	0.71	0.0	0.01
5yr CAGR Net Profit	46.24 %	17.47 %	-0.01 %
5yr Average Return on Assets	-1.84 %	9.52 %	13.18 %
Shareholdings
Promoter Holding	49.09 %	75.0 %	51.83 %
Share Pledged by Promoters	18.24 %	0.0	0.0
Change in Promoter Holding (3 Yrs)	-18.04 %	0.0	-6.17 %
Change in Mutual Fund Holding (3 Yrs)	7.53 %	3.46 %	19.94 %

Business

	Wockhardt	Astrazeneca Pharma I	Gland Pharma
Product Wise Break-Up	Product Wise Break-Up Pharmaceutical 100.0 Clinical trials 0 Pharmaceutical products 0 Injectables 0	Product Wise Break-Up Clinical Trial 6.94 Pharmaceutical 0 Injectables 0 Pharmaceutical 93.06	Product Wise Break-Up Clinical trials 0 Pharmaceutical 0 Injectables 0 Pharmaceutical products 0 Others 100
Location Wise Break-Up	Location Wise Break-Up Europe 24.69 India 15.72 Rest of the World 10.21 USA 3.45 Canada, Australia & New Zealand 0 Australia 0 Canada 0 Others 45.93	Location Wise Break-Up Canada, Australia & New Zealand 0 Europe 0 Canada 0 India 93.61 USA 0 Australia 0 Rest of the World 6.39	Location Wise Break-Up Canada, Australia & New Zealand 3.32 Europe 19.12 Canada 0 India 4.06 USA 52.69 Australia 0 Rest of the World 0 Others 20.81
Asset Break-Up	Asset Break-Up Others 100	-	-